Pharmaceuticals Search Engine [selected websites]

Wednesday, March 26, 2008

Fovea Pharmaceuticals : Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa

Paris, France January 7, 2008 - Fovea Pharmaceuticals SA, which, last December 2007, raised $44M in a Series B financing, announced that its product, Recombinant human rod-derived cone viability factor (rh-RdCVF), has received designation as Orphan Medicinal Product from the European Commission, following the positive opinion from the European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Orphan Medicinal Product (COMP) for the treatment of retinitis pigmentosa, a genetic disease leading to progressive loss of vision. Fovea is currently conducting pre-clinical studies of RdCVF and has demonstrated efficacy in animal model of the disease... Fovea Pharmaceuticals' Press Release - PDF version -